代谢功能障碍相关脂肪性肝炎中衰老肝星状细胞的表型与个体发生
该研究整合衰老相关β-半乳糖苷酶活性检测、免疫染色、流式细胞术与单核RNA测序(snRNAseq),在人类及小鼠代谢功能障碍相关脂肪性肝炎(MASH)中全面刻画衰老肝星状细胞(HSC)的表型与起源;伪时间轨迹分析显示衰老HSC起源于活化HSC,uPAR表达随疾病阶段演变,早期更特异于活化和衰老HSC,晚期也表达于髓系细胞。
要点
- 伪时间轨迹分析显示MASH中衰老HSC由活化HSC演变而来。
- uPAR在MASH中表达,其幅度与细胞特异性随疾病阶段演变。
- 早期uPAR更特异于活化和衰老HSC;晚期也表达于Trem2+巨噬细胞等髓系细胞。
核心结论
- 这些数据定义了人类和小鼠MASH中HSC衰老的特征,为未来抗纤维化治疗靶向这些细胞建立了重要蓝图。
研究设计与样本
- 研究整合衰老相关β-半乳糖苷酶活性检测、免疫染色、流式细胞术与单核RNA测序(snRNAseq),在人类及小鼠MASH中表征衰老HSC并定义其起源。
主要发现
- 伪时间轨迹分析显示衰老HSC起源于活化HSC。
- uPAR在MASH中表达,其表达幅度与细胞特异性随疾病阶段演变。
- 早期疾病中uPAR更特异于活化和衰老HSC;晚期疾病中uPAR也表达于髓系细胞,包括Trem2+巨噬细胞和髓系来源抑制细胞。
- 研究鉴定出人类及小鼠MASH衰老HSC表达的新表面蛋白,可被利用作为治疗靶点;摘要提及包括甘露糖受体CD206在内的五种其他新蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatic stellate cells (HSCs) are the key drivers of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), the fastest growing cause of hepatocellular carcinoma (HCC) worldwide. HSCs are heterogenous, and a senescent subset of HSCs is implicated in hepatic fibrosis and HCC. Administration of anti-uPAR (urokinase-type plasminogen activator receptor) CAR T cells has been shown to deplete senescent HSCs and attenuate fibrosis in murine models. However, the comprehensive features of senescent HSCs in MASH, as well as their cellular ontogeny have not been characterized; hence, we aimed to comprehensively characterize and define the origin of HSCs in human and murine MASH. METHODS: To comprehensively characterize the phenotype and ontogeny of senescent HSCs in human and murine MASH, we integrated senescence-associated beta galactosidase activity with immunostaining, flow cytometry and single-nucleus RNA sequencing (snRNAseq). We integrated the immunohistochemical profile with a senescence score applied to snRNAseq data to characterize senescent HSCs and mapped the evolution of uPAR expression in MASH. RESULTS: Using pseudotime trajectory analysis, we establish that senescent HSCs arise from activated HSCs. While uPAR is expressed in MASH, the magnitude and cell-specificity of its expression evolve with disease stage. In early disease, uPAR is more specific to activated and senescent HSCs, while it is also expressed by myeloid-lineage cells, including Trem2+ macrophages and myeloid-derived suppressor cells, in late disease. Furthermore, we identify novel surface proteins expressed on senescent HSCs in human and murine MASH that could be exploited as therapeutic targets. CONCLUSIONS: These data define features of HSC senescence in human and murine MASH, establishing an important blueprint to target these cells as part of future antifibrotic therapies. IMPACT AND IMPLICATIONS: Hepatic stellate cells (HSCs) are the primary drivers of scarring in chronic liver diseases. As injury develops, a subset of HSCs become senescent; these cells are non-proliferative and pro-inflammatory, thereby contributing to worsening liver injury. Here we show that senescent HSCs are expanded in MASH (metabolic dysfunction-associated steatohepatitis) in humans and mice, and we trace their cellular origin from the activated HSC subset. We further characterize expression of uPAR (urokinase plasminogen activated receptor), a protein that marks senescent HSCs, and report that uPAR is also expressed by activated HSCs in early injury, and in immune cells as liver injury advances. We have integrated high-resolution single-nucleus RNA sequencing with immunostaining and flow cytometry to identify five other novel proteins expressed by senescent HSCs, including mannose receptor CD206, which will facilitate future therapeutic development.
引用
- Yashaswini CN, Qin T, Bhattacharya D, et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J Hepatol. 2024. PMID: 38508241. doi:10.1016/j.jhep.2024.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。